SG11202007119UA - Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof - Google Patents

Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof

Info

Publication number
SG11202007119UA
SG11202007119UA SG11202007119UA SG11202007119UA SG11202007119UA SG 11202007119U A SG11202007119U A SG 11202007119UA SG 11202007119U A SG11202007119U A SG 11202007119UA SG 11202007119U A SG11202007119U A SG 11202007119UA SG 11202007119U A SG11202007119U A SG 11202007119UA
Authority
SG
Singapore
Prior art keywords
dihydrotriazinone
dihydropyrimidinone
fused
saturated
compounds
Prior art date
Application number
SG11202007119UA
Other languages
English (en)
Inventor
Masahiro Yokota
Noriyoshi Seki
Eiichi Watanabe
Shingo Fujioka
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of SG11202007119UA publication Critical patent/SG11202007119UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202007119UA 2018-02-28 2019-02-27 Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof SG11202007119UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035601 2018-02-28
PCT/JP2019/007435 WO2019167982A1 (fr) 2018-02-28 2019-02-27 Composé dihydropyrimidinone ou dihydrotriazinone condensé à cycle saturé, et utilisation pharmaceutique de celui-ci

Publications (1)

Publication Number Publication Date
SG11202007119UA true SG11202007119UA (en) 2020-08-28

Family

ID=67805013

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007119UA SG11202007119UA (en) 2018-02-28 2019-02-27 Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof

Country Status (18)

Country Link
US (2) US20190300490A1 (fr)
EP (1) EP3760619B1 (fr)
JP (1) JP7200005B2 (fr)
KR (1) KR20200127177A (fr)
CN (1) CN111741948B (fr)
AR (1) AR123121A1 (fr)
AU (1) AU2019228916A1 (fr)
BR (1) BR112020016784A2 (fr)
CA (1) CA3088000A1 (fr)
CL (1) CL2020002188A1 (fr)
IL (1) IL276326A (fr)
MX (1) MX2020008929A (fr)
PE (1) PE20210447A1 (fr)
PH (1) PH12020551342A1 (fr)
RU (1) RU2020131405A (fr)
SG (1) SG11202007119UA (fr)
TW (1) TW202000652A (fr)
WO (1) WO2019167982A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
RU2020131405A (ru) 2018-02-28 2022-03-24 Джапан Тобакко Инк. Сконденсированные с насыщенным кольцом дигидропиримидиноновые или дигидротриазиноновые соединения и их применение в фармацевтике
WO2023232870A1 (fr) 2022-05-31 2023-12-07 Immunic Ag Modulateurs de rorg/rorgt pour le traitement d'infections virales de type covid-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080029965A (ko) 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
MX2009013131A (es) * 2007-06-01 2010-01-15 Schering Corp Moduladores de gamma secretasa.
AU2009239536C1 (en) * 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
WO2013064231A1 (fr) * 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag Sulfonamides à sept chaînons comme modulateurs des récepteurs gamma orphelins associés à un récepteur de l'acide rétinoïque (rorγ, nr1f3)
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
CA2938311C (fr) 2014-02-03 2023-03-07 Vitae Pharmaceuticals, Inc. Inhibiteurs de ror-gamma a base de dihydropyrrolopyridine
WO2016085780A1 (fr) 2014-11-25 2016-06-02 Merck Sharp & Dohme Corp. Composés iminopyrimidinones condensés oxacycliques en c5-c6 utilisés comme inhibiteurs de bace, compositions et utilisation associées
MX371128B (es) 2014-12-12 2020-01-17 Japan Tobacco Inc Compuestos de dihidropirimidin-2-ona y su uso medico.
CN108463458B (zh) 2015-11-20 2022-02-01 生命医药有限责任公司 ROR-γ的调节剂
RU2020131405A (ru) 2018-02-28 2022-03-24 Джапан Тобакко Инк. Сконденсированные с насыщенным кольцом дигидропиримидиноновые или дигидротриазиноновые соединения и их применение в фармацевтике

Also Published As

Publication number Publication date
AR123121A1 (es) 2022-11-02
CA3088000A1 (fr) 2019-09-06
PH12020551342A1 (en) 2021-06-21
CL2020002188A1 (es) 2020-12-18
TW202000652A (zh) 2020-01-01
CN111741948B (zh) 2023-11-10
JP7200005B2 (ja) 2023-01-06
US20220119355A1 (en) 2022-04-21
EP3760619B1 (fr) 2023-10-25
BR112020016784A2 (pt) 2021-01-12
KR20200127177A (ko) 2020-11-10
EP3760619A1 (fr) 2021-01-06
MX2020008929A (es) 2020-10-01
AU2019228916A1 (en) 2020-07-02
CN111741948A (zh) 2020-10-02
EP3760619A4 (fr) 2021-07-07
US11834421B2 (en) 2023-12-05
US20190300490A1 (en) 2019-10-03
WO2019167982A1 (fr) 2019-09-06
IL276326A (en) 2020-09-30
JP2019151624A (ja) 2019-09-12
PE20210447A1 (es) 2021-03-08
RU2020131405A (ru) 2022-03-24

Similar Documents

Publication Publication Date Title
HUE052749T2 (hu) Meloxicamot és rizatriptant tartalmazó gyógyászati készítmények
IL290745A (en) A pyrimidine compound and its pharmaceutical use
IL273339A (en) Griseofulbin compound and its medical use
IL276326A (en) Dihydropyrimidinone or dihydrotriazinone compounds with a saturated compressed ring and their pharmaceutical use
IL277502A (en) Compounds and uses for them
IL284514A (en) Halo-allylamine compounds and their use
IL278142A (en) Antiproliferative compounds and their uses
IL312725A (en) Palladianolide compounds and their use
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
IL279483A (en) Cyanotriazole compounds and their uses
IL280644A (en) Magnesium serine compound and its use
IL281357A (en) Cd73 inhibitors and their pharmacological uses
GB201804098D0 (en) Novel compounds and therapeutic uses thereof
EP3718543A4 (fr) Composition pharmaceutique et son utilisation
IL282157A (en) Compounds and their medicinal uses
IL283315A (en) Heterocyclic compounds and medical use thereof
IL292646A (en) Pharmaceutical combination and its use
HK1252052A1 (zh) 胍化合物及其用途
IL283540A (en) Dock1 inhibitory compound and use thereof
KR102483492B9 (ko) 2,5-이치환된 피리미딘 유도체 및 이를 포함하는 약학적 조성물
GB201816553D0 (en) Novel compounds and therapeutic uses thereof
GB201813311D0 (en) Novel compounds and their use
GB201802743D0 (en) Medicament and use thereof
HK1254527A1 (zh) 藥物調配物和其用途